Form 4: Nautilus Biotechnology Executive Gwen E. Weld Reports Stock Option Grant
SEC Form 4 Filing
Gwen E. Weld, Chief People Officer of Nautilus Biotechnology, reports the acquisition of stock options.
Summary
- Gwen E. Weld, Chief People Officer of Nautilus Biotechnology, filed a Form 4 on March 4, 2024, reporting a transaction on March 1, 2024.
- Weld acquired 160,000 stock options with an exercise price of $2.72.
- These options vest over time, starting with 25% vesting on January 1, 2025 (one year after the Vesting Commencement Date of January 1, 2024), and the remaining shares vesting monthly thereafter.
- The options expire on March 1, 2034.
- Following the transaction, Weld directly owns 160,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.
Positives
- The grant of stock options to the Chief People Officer aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and contribution to the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotechnology companies.
- The vesting schedule described is typical, with vesting occurring over a multi-year period contingent on continued employment.
- The specific number of options granted and the exercise price would be benchmarked against similar roles and company size within the biotech sector.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
- The grant incentivizes the executive to remain with the company, providing stability.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Vesting Commencement Date |
| March 1, 2024 | Transaction Date: Stock options acquired |
| March 4, 2024 | Date of Form 4 Filing |
| January 1, 2025 | First vesting date (25% of options) |
| March 1, 2034 | Expiration Date of Stock Options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.